Trachoma and antibiotic use: The A' in SAFE

Expert Review of Anti-Infective Therapy

Volumn 10, Issue 1, 2012, Pages 75-83

  West, Sheila ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

azithromycin; Chlamydia trachomatis; mass treatment; neglected tropical disease; tetracycline; trachoma

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; SULFONAMIDE; TETRACYCLINE;

ABDOMINAL PAIN; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL TRANSMISSION; BACTERIUM ISOLATION; BLURRED VISION; CHLAMYDIA TRACHOMATIS; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; COMMUNITY CARE; COST OF ILLNESS; COUGHING; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TISSUE LEVEL; DRUG USE; DRUG WITHDRAWAL; ENDEMIC DISEASE; EYELID RECONSTRUCTION; FEVER; GASTROINTESTINAL SYMPTOM; HEALTH CARE PLANNING; HELMINTHIASIS; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; NAUSEA; NONHUMAN; PATIENT COMPLIANCE; PATIENT SAFETY; PRACTICE GUIDELINE; PREVENTIVE HEALTH SERVICE; PUBLIC HEALTH PROBLEM; RECOMMENDED DRUG DOSE; REVIEW; RISK REDUCTION; SINGLE DRUG DOSE; STEVENS JOHNSON SYNDROME; TRACHOMA; TROPICAL DISEASE; VERTICAL TRANSMISSION; VISUAL IMPAIRMENT; VOMITING;

ANTI-BACTERIAL AGENTS; BLINDNESS; CHILD; CHILD, PRESCHOOL; CHLAMYDIA TRACHOMATIS; DISEASE ERADICATION; DISEASE RESERVOIRS; HUMANS; PREVENTIVE HEALTH SERVICES; TRACHOMA; WORLD HEALTH ORGANIZATION;

EID: 83455236511     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.11.150     Document Type: Review

References (62)

1. Resnikoff S, Pascolini D, Etyaale D, et al. Global data on visual impairment in the year 2002. Bull. World Health Organ. 82, 844-851 (2004).
2. World Health Organization. WHA51.11 World Health Assembly (Ed.) (1998).
3. Mariotti S, Pascolini D, Rose-nussbaumer J. Trachoma: global magnitude of a preventable cause of blindness. Br. J. Ophthalmol. 93, 563-568 (2009).
4. Frick KD, Hanson CL, Jacobson GA. Global burden of trachoma and economics of the disease. Am. J. Trop. Med. Hyg. 69, 1-10 (2003).
5. Courtright P, Sheppard J, Lane S, Sadek A, Schachter J, Dawson CR. Latrine ownership as a protective factor in inflammatory trachoma in Egypt. Br. J. Ophthalmol. 75, 322-325 (1991).
6. West SK, Munoz B, Turner VM, Mmbaga BBO, Taylor HR. The epidemiology of trachoma in Central Tanzania. Int. J. Epidemiol. 20, 1088-1092 (1991).
7. Katz J, Zeger S, Tielsch L. Village and household clustering of xerophthalmia and trachoma. Int. J. Epidemiol. 17, 865-869 (1988).
8. Blake IM, Burton MJ, Bailey RL, et al. Estimating household and community transmission of ocular Chlamydia trachomatis. PLoS Negl. Trop. Dis. 3, e401 (2009).
9. Bailey R, Osmond C, Mabey DC, Whittle HC, Ward ME. Analysis of the household distribution of trachoma in a Gambian village using a Monte Carlo simulation procedure. Int. J. Epidemiol. 18, 944-951 (1989).
10. West SK, Bailey R. Trachoma. In: The Epidemiology of Eye Disease. Johnson GJ, Minassian DC, Weale RA, West SK (Eds), Arnold, London, UK, 164-185 (2003).
11. Grayston J, Yeh L, Kuo C. Importance of reinfection in the pathogenesis of trachoma. Rev. Infect. Dis. 7, 717-725 (1985).
12. Taylor HR, Johnson SL, Prendergast RA, Schachter J, Dawson CR, Silverstein AM. An animal model of trachoma: the importance of repeated reinfection. Invest. Ophthalmol. Vis. Sci. 23, 507-515 (1982).
13. Reinhards JWA, Nižeti B, Kupka K, Maxwell-Lyons F. Studies on the epidemiology and control of seasonal conjunctivitis and trachoma in southern Morocco. Bull. World Health Organ. 39, 497-545 (1968).
14. Muñoz B, Bobo L, Mkocha H, Lynch M, Hsieh YH, West S. Incidence of trichiasis in a cohort of women with and without scarring. Int. J. Epidemiol. 28, 1167-1171 (1999).
15. Bernauer WBD, Wright P. Chronic progressive conjunctival cicatrisation. Eye 7, 371-378 (1993).
16. Burton MJ, Bowman RJ, Faal H, et al. Long term outcome of trichiasis surgery in the Gambia. Br. J. Ophthalmol. 89, 575-579 (2005).
17. Thylefors B, Dawson C, Jones BR, West SK, Taylor HR. A simple system for the assessment of trachoma and its complications. Bull. World Health Organ. 65, 477-483 (1987).
18. West ES, Munoz B, Mkocha H, et al. Mass treatment and the effect on the load of Chlamydia trachomatis infection in a trachoma-hyperendemic community. Invest. Ophthalmol.Vis. Sci. 46, 83-87 (2005).
19. Keenan JDLT, Alemayehu W, Melese M, et al. Slow resolution of clinically active trachoma following successful mass antibiotic treatments. Arch. Ophthalmol. 129, 512-513 (2011).
20. Burton MJ, Hu VH, Massae P, et al. What is causing active trachoma? The role of nonchlamydial bacterial pathogens in a low prevalence setting. Invest. Ophthalmol. Vis. Sci. 52(8), 6012-6017 (2011).
21. Ngondi J, Gebre T, Shargie EB, et al. Evaluation of three years of the SAFE strategy (Surgery, Antibiotics, Facial cleanliness and Environmental improvement) for trachoma control in five districts of Ethiopia hyperendemic for trachoma. Trans. R. Soc. Trop. Med. Hyg. 103(10), 1001-1010 (2009).
22. Ngondi J, Onsarigo A, Matthews F, et al. Effect of 3 years of SAFE (surgery, antibiotics, facial cleanliness, and environmental change) strategy for trachoma control in southern Sudan: a cross-sectional study. Lancet 368, 589-595 (2006).
23. Girard AEGD, English AR, Gootz TD, et al. Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution. Antimicrob. Agents Chemother. 12, 1948-1954 (1987).
24. Huguet PBL, Einterz EM, Goldschmidt P, Bensaid P. Mass treatment of trachoma with azithromycin 1.5% eye drops in the Republic of Cameroon: feasibility, tolerance and effectiveness. Br. J. Ophthalmol. 94, 157-160 (2010).
25. Schachter J, West SK, Mabey D, et al. Azithromycin in control of trachoma. Lancet 354, 630-635 (1999).
26. Bowman RJ, Sillah A, Van Dehn C, et al. Operational comparison of single-dose azithromycin and topical tetracycline for trachoma. Invest. Ophthalmol. Vis. Sci. 41, 4074-4079 (2000).
27. Taylor HR. Trachoma; a blinding scourge from the bronze age to the twenty first century (1st Edition), Center for Eye Research, Australia (2008).
28. Evans JRSA. Antibiotics for trachoma. Cochrane Database Syst. Rev. 3, CD001860 (2011).
29. WHO Working Group. Report of the eighth meeting of the WHO alliance for the global elimination of blinding trachoma. World Health Organization, Geneva, Switzerland. WHO/PBD/GET/04.2 (2004).
30. Solomon AW, Holland MJ, Alexander ND, et al. Mass treatment with single-dose azithromycin for trachoma. N. Engl. J. Med. 351, 1962-1971 (2004).
31. West SK, Munoz B, Mkocha H, et al. Infection with Chlamydia trachomatis after mass treatment of a trachoma hyperendemic community in Tanzania: a longitudinal study. Lancet 366, 1296-1300 (2005).
32. Broman AT, Shum K, Munoz B, Duncan DD, West SK. Spatial clustering of ocular chlamydial infection over time following treatment, among households in a village in Tanzania. Invest. Ophthalmol. Vis. Sci. 47, 99-104 (2006).
33. Lietman T, Porco T, Dawson C, Blower S. Global elimination of trachoma: how frequently should we administer mass chemotherapy? Nat. Med. 5, 572-576 (1999).
34. Whitty CJ, Glasgow KW, Sadiq ST, Mabey DC, Bailey R. Impact of community-based mass treatment for trachoma with oral azithromycin on general morbidity in Gambian children. Pediatr. Infect. Dis. J. 18, 955-958 (1999).
35. Fry AM, Jha HC, Lietman TM, et al. Adverse and beneficial secondary effects of mass treatment with azithromycin to eliminate blindness due to trachoma in Nepal. Clin. Infect. Dis. 35, 395-402 (2002).
36. Ayele B, Gebre T, House JI, et al. Adverse events after mass azithromycin treatments for trachoma in Ethiopia. Am. J. Trop. Med. Hyg. 85, 291-294 (2011).
37. Batt SL, Charalambous BM, Solomon AW, et al. Impact of azithromycin administration for trachoma control on the carriage of antibiotic-resistant Streptococcus pneumoniae. Antimicrob. Agents Chemother. 47, 2765-2769 (2003).
38. Gaynor BD, Holbrook KA, Whitcher JP, et al. Community treatment with azithromycin for trachoma is not associated with antibiotic resistance in Streptococcus pneumoniae at 1 year. Br. J. Ophthalmol. 87, 147-148 (2003).
39. Skalet AHCV, Ayele B, Gebre T, et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster-randomized clinical trial. PLoS Med. 7, e1000377 (2010).
40. Gaynor BD, Chidambaram JD, Cevallos V, et al. Topical ocular antibiotics induce bacterial resistance at extraocular sites. Br. J. Ophthalmol. 89, 1097-1099 (2005).
41. Bhengraj ARVH, Srivastava P, Salhan S, Mittal A. Decreased susceptibility to azithromycin and doxycycline in clinical isolates of Chlamydia trachomatis obtained from recurrently infected female patients in India. Chemotherapy 56, 371-377 (2010).
42. West SK, West ES, Alemayehu W, et al. Single-dose azithromycin prevents trichiasis recurrence following surgery: randomized trial in Ethiopia. Arch. Ophthalmol. 124, 309-314 (2006).
43. Holm SO, Jha HC, Bhatta RC, et al. Comparison of two azithromycin distribution strategies for controlling trachoma in Nepal. Bull. World Health Organ. 79, 194-200 (2001).
44. Frick KD, Lietman TM, Holm SO, Jha HC, Chaudhary JS, Bhatta RC. Cost-effectiveness of trachoma control measures: comparing targeted household treatment and mass treatment of children. Bull. World Health Organ. 79, 201-207 (2001).
45. Ssemanda EN, Munoz B, Harding-Esch EM, et al. Mass treatment with azithromycin for trachoma control: participation clusters in households. PLoS Negl. Trop. Dis. 4(10), pii: e838 (2010).
46. Melese M, Alemayehu W, Lakew T, et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA 299, 778-784 (2008).
47. Burton MJ, Holland MJ, Makalo P, et al. Re-emergence of Chlamydia trachomatis infection after mass antibiotic treatment of a trachoma-endemic Gambian community: a longitudinal study. Lancet 365, 1321-1328 (2005).
48. West SK, Munoz B, Mkocha H, Gaydos C, Quinn T. Trachoma and ocular Chlamydia trachomatis were not eliminated three years after two rounds of mass treatment in a trachoma hyperendemic village. Invest. Ophthalmol. Vis. Sci. 48, 1492-1497 (2007).
49. Lakew T, House J, Hong KC, et al. Reduction and return of infectious trachoma in severely affected communities in ethiopia. PLoS Negl. Trop. Dis. 3, e376 (2009).
50. Cajas-Monson LC, Mkocha H, Muñoz B, Quinn TC, Gaydos CA, West SK. Risk factors for ocular infection with Chlamydia trachomatis in children 6 months following mass treatment in Tanzania. PLoS Negl. Trop. Dis. 5, e978 (2011).
51. West SK, Stare D, Mkocha H, Munoz B, Gaydos C, Quinn TC. Do infants increase the risk of re-emergent infection in households after mass drug administration for trachoma? Invest. Ophthalmol. Vis. Sci. 52(8), 6040-6042 (2011).
52. Campbell JP, Mkocha H, Munoz B, West SK. Randomized trial of high dose azithromycin compared to standard dosing for children with severe trachoma in Tanzania. Ophthalmic. Epidemiol. 16, 175-180 (2009).
53. West SK, Munoz B, Mkocha H, Gaydos C, Quinn T. Number of years of annual mass treatment with azithromycin needed to control trachoma in hyper-endemic communities in Tanzania. J. Infect. Dis. 204, 268-273 (2009).
54. Frick KD, West SK. The SAFE strategy for trachoma control: planning a cost-effectiveness analysis of the antibiotic component and beyond. Ophthalmic Epidemiol. 8, 205-214 (2001).
55. Solomon AW, Akudibillah J, Abugri P, et al. Pilot study of the use of community volunteers to distribute azithromycin for trachoma control in Ghana. Bull. World Health Organ. 79, 8-14 (2001).
56. Lynch M, West S, Frick K, Mkocha H. Azithromycin treatment coverage in Tanzanian children using community volunteers. Ophthalmic Epidemiol. 10, 167-175 (2003).
57. Basilion EV, Kilima PM, Mecaskey JW. Simplification and improvement of height-based azithromycin treatment for paediatric trachoma. Trans. R. Soc. Trop. Med. Hyg. 99, 6-12 (2005).
58. Hotez PJ, Molyneux DH, Fenwick A, et al. Control of neglected tropical diseases. N. Engl. J. Med. 357, 1018-1027 (2007).
59. Linehan MCHC, Weaver A, Baker M, et al. Integrated implementation of programs targeting neglected tropical diseases through preventive chemotherapy: proving the feasibility at national scale. Am. J. Trop. Med. Hyg. 84, 5-14 (2011).
60. World Health Organization. Report of the first meeting of WHO strategic and technical advisory group on neglected tropical diseases. World Health Organization, Geneva, Switzerland (2007).
61. Koukounari ATS, Donnelly CA, Ouedraogo A, et al. Integrated monitoring and evaluation and environmental risk factors for urogenital schistosomiasis and active trachoma in Burkina Faso before preventative chemotherapy using sentinel sites. BMC Infect. Dis. 11, 191 (2011).
62. RTI, Inc./USAID 2011 Consultancy Report on Nepal National Trachoma Control Program. http://ntd.rti.org/publications/index. cfm?fuseaction= throwpub&id=327